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Background: The mechanisms that underlie autophagy in cerebral ischemia remain poorly defined. Myeloid cell
leukemia-1 (Mcl1), an anti-apoptotic member of the Bcl-2 family of proteins, regulates the balance between
autophagy and apoptosis. However, little is known regarding its expression profile and contribution to cell fate in
the brain following ischemic stroke.
Results: In this study, we investigated the expression profile and cellular distribution of Mcl1 in brains from
transient middle cerebral artery occlusion (MCAO) model rats. Brain slices from sham-operated control rats showed
minimal immunoreactivity for Mcl1. Mcl1 was mainly produced in neurons. Immunoreactivity for Mcl1 increased as
early as 4 hours after MCAO, peaked at 24 hours, and then declined, but still remained high, at 72 hours. Mcl1
positive cells never colocalized with either cleaved caspase-3 or terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling-positive cells. Both microtubule-associated protein 1 light chain 3 (LC3) and beclin-1 were
evident in ischemic brain between 4 and 72 hours after MCAO. Most cells with strong LC3 staining were also
labeled with beclin-1. Beclin-1 did colocalize with caspase-3 or Mcl1. Beclin-1/caspase-3 positive cells displayed the
characteristic features of apoptosis including cell shrinkage and pyknotic nuclei, whereas beclin-1/Mcl1 positive cells
had normal morphology. Pretreatment with 3-methyladenine attenuated autophagy without affecting the level of
Mcl1 protein.
Conclusions: These findings demonstrate that the expression of Mcl1 is involved in the survival of neuronal cells. In
addition, the coexpression of Mcl1 with beclin-1 may attenuate beclin-1-dependent autophagy during ischemic
stroke in rats.
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Autophagy is an intracellular lysosomal degradation pro-
cess, which is characterized by the formation of double-
membraned autophagosomes. Substantial reports have
documented that ischemia-induced autophagy leads to
neuronal death following ischemic stroke [1,2]. This
autophagy-dependent non-apoptotic cell death is de-
fined as autophagic cell death, or type II programmed
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reproduction in any medium, provided the orautophagic vacuoles [2,3]. However, the mechanism by
which ischemia-induced autophagy promotes cell death
remains unclear. Physiologically, autophagy is tightly
modulated by regulators to prevent unbalanced activa-
tion. Several regulators, particularly the Bcl-2 family of
proteins, also have a critical role in the regulation of
apoptosis, suggesting that the integrated regulation of
autophagy and apoptosis determines cell fate [4]. The
Bcl-2 homologue, myeloid cell leukemia 1 (Mcl1), is an
anti-apoptotic member of the Bcl-2 family of proteins.
Mcl1 is a mitochondrial protein [5] and is believed to in-
hibit cell death through interactions with pro-apoptotic
Bcl-2 family members [6]. Furthermore, Mcl1 also has aral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, little is known about the expression profile
and functions of Mcl1 in the brain following cerebral
ischemia.
In this study, we investigated the expression and
cellular localization of Mcl1 in the brains of transient
middle cerebral artery occlusion (MCAO) model rats.
In addition, we examined the potential involvement of
Mcl1 in ischemia-induced autophagy following ische-
mic stroke.
Results
Expression of Mcl1 in brain from MCAO rats
Expression levels of Mcl1 were detected in rats subjected
to 1-hour focal ischemia followed by 4, 24 or 72 hours
reperfusion. Sparse Mcl1 immunoreactivity was seen in
the cortex and striatum of the sham-operated control ratsFigure 1 Expression of Mcl1 in brains from rats subjected to middle c
of a coronal brain section. The square fields represent observed regions (a)
brains from sham-operated control (b) and MCAO group (4 h, 24 h, 72 h, c
mean ± SD from four independent experiments. *P < 0.001 vs. control grou
co-localization of Mcl1 and DAPI indicated Mcl1was mainly localized in the
protein levels were elevated in MCAO group at each time point compared
analyzed with Image J 1.42q and normalized to the loading control (β-actin
experiments. *P < 0.001 vs. control group, #P < 0.001 vs. the previous time p(Figure 1A, b). Mcl1 immunoreactivity started to increase
at 4 hours, and further increased at 24 hours. Mcl1 immu-
noreactivity had declined at 72 hours after 1 hour MCAO,
but was still highly expressed (Figure 1A, c-e). Quantifica-
tion confirmed that the numbers of strongly Mcl1 immu-
noreactive cells were significantly higher in the ipsilateral
ischemic cortex and striatum at all time points compared
with the control animals (n = 4/group, *P < 0.001 com-
pared with the control groups, #P < 0.001 compared with
the previous time point; Figure 1A, f ). At the subcel-
lular level, Mcl1 was mainly localized in the cytoplasm
(Figure 1B). Western blot analysis further confirmed that
Mcl1 protein levels were elevated in the ipsilateral cere-
bral cortex and the striatum at all time points when com-
pared with sham-operated control animals (n = 4/group,
*P < 0.001 compared with control group, #P < 0.001 com-
pared with the previous time point; Figure 1C). These dataerebral artery occlusion (MCAO). (A) A schematic representation
. Immunofluorescent staining showed the expression of Mcl1 in
-e). Quantification of Mcl1-positive cells (f). Results were expressed as
p, #P < 0.001 vs. the previous time point. Scale bars = 50 μm. (B) The
cytoplasm. Scale bars = 50μm. (C) Western blot confirmed that Mcl1
with control group. Optical densities of respective protein bands were
). Results were expressed as mean ± SD from four independent
oint.
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and striatal neurons in a time-dependent manner.
Cell distribution of Mcl1 in rat brain after MCAO
Cell distribution of Mcl1 expression was further in-
vestigated in ischemic brains after MCAO. Antibodies
against neuronal nuclei (NEUN), glial fibrillary acidic
protein (GFAP) and OX-42 were used to identify neu-
rons, astrocytes and microglia/macrophages, respectively.
The overwhelming majority of Mcl1 (red) was labeled
with NEUN-positive neurons (green) (Figure 2A). By con-
trast, only a few Mcl1 positive cells were GFAP-positive
astrocytes (green; Figure 2B) or OX42-positive microglia/Figure 2 Cellular distribution of Mcl1 in rat brain after middle cerebra
the overwhelming majority of Mcl1 co-localized with NEUN-positive neuron
GFAP-positive astrocytes (B) or OX42-positive microglia/macrophages (C). (
co-localize with caspase-3 or TUNEL positive cells in the ischemic brain, resmacrophages (green; Figure 2C), indicating that neurons
were the major cell type expressing Mcl1 in the ischemic
brain. Double labeling indicated that Mcl1 positive cells
did not co-localize with caspase-3 positive cells in the
ischemic area (Figure 2D). Furthermore, Mcl1-positive
cells were never positive for TUNEL in the ischemic
area (Figure 2E), even in the center of the lesion, where
TUNEL-positive cells were found at all time points.
Upregulation of beclin-1 partly contributed to cell death
Beclin-1 immunoreactivity was weak in brains from sham-
operated control rats (Figure 3A, a, left panel). Beclin-1
positive cells increased in the ipsilateral hemisphere in al artery occlusion (MCAO). (A) Double immunostaining showed
s. By contrast, only a few Mcl1 positive cells were labeled with
D-E) Double staining indicated that Mcl1 positive cells did not
pectively. Cont: control group. Scale bars = 50 μm.
Figure 3 Upregulation of beclin-1 partly contributed to cell death. (A) Double immunostaining showed the co-localization of beclin-1 and
caspase-3 in brains from the control (a) and MCAO group (4 h, 24 h, 72 h, b-d). Almost all cells with strong LC3 staining were labeled with
beclin-1(e). (B) Quantification of beclin-1+, caspase-3+ and beclin-1+/caspase-3+ cells. (C) Western blot analysis of protein levels of beclin-1, LC3
and β-actin in the rat cortex and striatum derived from the control and MCAO group. Optical densities of respective protein bands were analyzed
with Image J 1.42q and normalized to the loading control (β-actin). Results were expressed as mean ± SD from four independent experiments.
*P < 0.001 vs. control group, #P < 0.001 vs. the previous time point. Cont: control group. Scale bars = 50 μm.
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positive cells started to increase at 4 hours, reaching a
peak at 24 hours and declining at 72 hours, but still
remained highly expressed after 1 hour of focal cerebral
ischemia (Figure 3A, b-d, left panel). Western blotting in-
dicated that beclin-1 protein levels were elevated in the ip-
silateral ischemic cerebral cortex and the striatum at all
time points when compared with sham-operated control
animals (Figure 3C, a). Quantification demonstrated that
the numbers of beclin-1 immunoreactive cells and the
levels of beclin-1 protein changed from 4 to 72 hours in
the ipsilateral ischemic cortex and striatum (n = 4/group,
*P < 0.001 compared with control group, #P < 0.001 com-
pared with the previous time point; Figure 3B; C, a). LC3
has been used as a specific marker to monitor autophagy.
In the present study, almost all cells with strong punctateLC3 staining were labeled with beclin-1 (Figure 3A, e).
A similar expression pattern of LC3 and beclin-1
(Figure 3C), indicated that beclin-1 was a major com-
ponent in ischemia-induced autophagy.
In order to investigate the relationship between auto-
phagy and apoptosis, brain sections were double-labeled
with antibodies against beclin-1 and cleaved caspase-3.
The results showed that many beclin-1 expressing cells
were negative for cleaved caspase-3, whereas only a small
proportion of beclin-1 expressing cells, particularly those
located closer to the center of the lesion, were cleaved
caspase-3 positive (Figure 3A, a−d). Semi-quantitative as-
sessment showed that among the beclin-1 positive cells,
approximately 12.5% of the cells were caspase-3 positive
in the sham group, while approximately 21.2% at 4 hours,
38.7% and 28.3% at 24 hours and 72 hours, respectively,
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group, *P < 0.001 compared with control group, #P < 0.001
compared with the previous time point; Figure 3B). Thus,
the results suggested that upregulation of beclin-1 was
partially implicated in cell death.
Mcl1 potentially modulated beclin-1-induced autophagy
Mcl1 is a stress sensor that regulates autophagy and the
balance between autophagy and apoptosis [7,8]. Many
Mcl1 positive cells also expressed beclin-1 at different
time points (Figure 4A, a-d). Semi-quantitative assess-
ment showed that approximately 35.3% beclin-1 positive
cells expressed both beclin-1 and Mcl1 in the ipsilateralFigure 4 Mcl1 potentially modulated beclin-1-induced autophagy. (A)
and Mcl1 in brains from control (a) and MCAO group (4 h, 24 h, 72 h, b-d)
beclin-1+/caspase-3+ cells in control and MCAO group. Results were expres
control group, #P < 0.001 vs. the previous time point. (C) Some beclin-1exp
cell shrinkage and pyknotic nuclei (small arrow), whereas those cells coexp
their nuclei were not pyknotic, as demonstrated by co-labeling with DAPI (
blocked autophagy but did not affect the protein levels of Mcl1. Western b
group compared with that of NS group (a). However, Mcl1 protein levels re
after autophagy inhibition (b). Optical densities of respective protein bands
control (β-actin). Results were expressed as mean ± SD from four independ
NS group. Cont: control group. Scale bars = 50 μm (in A), 20 μm (in C).hemisphere of the control group. Approximately 44.9%,
56.1%, and 50.9% of cells were double labeled in the
ipsilateral ischemic hemisphere at 4, 24 and 72 hours,
respectively (n = 4/group, *P < 0.001 compared with con-
trol group, #P < 0.001 compared with the previous time
point; Figure 4B). Results indicated Mcl1 and beclin-1
may operate together in the same cells after ischemic
reperfusion. Interestingly, some beclin-1 expressing cells
displayed the characteristic features of apoptosis in-
cluding cell shrinkage and pyknotic nuclei (Figure 4C,
small arrow), whereas those cells coexpressing Mcl1 and
beclin-1 displayed little chromatin clumping, and their
nuclei were not pyknotic as demonstrated by co-labelingDouble immunostaining showed the co-localization of beclin-1
. (B) Quantitative assessment the numbers of beclin-1+, Mcl1+ and
sed as mean ± SD from four independent experiments. *P < 0.001 vs.
ressing cells displayed the characteristic features of apoptosis including
ressing Mcl1 and beclin-1 displayed little chromatin clumping, and
big arrows). (D) Pretreatment with 3-MA before MCAO significantly
lot results showed the levels of LC3-II significantly decreased in 3-MA
mained unchanged in 3-MA group compared with that of NS group
were analyzed with Image J 1.42q and normalized to the loading
ent experiments. *P < 0.001 vs. control group; #P < 0.001, &P > 0.10 vs.
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suggested that Mcl1 potentially inhibited beclin-1-in-
duced cell death.
To further explore the relationship between Mcl1
and autophagy, rats were pretreated with 3-MA before
MCAO. Western blot results indicated that protein ex-
pression levels of Mcl1 were not affected after autophagy
was blocked by 3-MA pretreatment (Figure 4D, a-b.
&P > 0.10, #P < 0.001 compared with NS group; *P <
0.001 compared with control group). The present data
suggested that Mcl1 expression may lie upstream of
autophagosome formation and potentially modulate
beclin-1-induced autophagy.
Discussion
Mcl1 is a key regulator of apoptosis during central ner-
vous system development and after DNA damage [6,13].
Emerging data suggest that Mcl1 is critical for survival
of different cells, whereas inhibition of Mcl1 promotes
cell death [14-16]. In the present study, caspase-3 po-
sitive cells were not Mcl1 positive, while Mcl1 positive
cells were never TUNEL positive at all time points, sug-
gesting that Mcl1 was required for the survival of neural
cells following ischemic insult.
Autophagy has been well documented in different mo-
dels of cerebral ischemia. We consistently found that
autophagy, as evidenced by punctate LC3 staining, was
significantly increased following focal cerebral ischemia.
Furthermore, almost all beclin-1-upregulating cells dis-
played punctate LC3 fluorescence. This observation indi-
cated that cerebral ischemia may induce autophagy in a
beclin-1 dependent-manner. In addition, we found that a
subpopulation of beclin-1-positive cells also expressed
the active form of caspase-3. These results provided fur-
ther evidence to demonstrate the close connection bet-
ween beclin-1-dependent autophagy and cell death [17].
However, not all beclin-1 positive cells were caspase-3
positive, which indicated that not all the beclin-1 posi-
tive cells were predestined to die following stroke [18].
Interestingly, some beclin-1 positive cells were also Mcl1
positive, suggesting ischemia-induced coexpression of
beclin-1 and Mcl1 in some neural cells. The beclin-1/
Mcl1 positive cells had normal morphology and their nu-
clei were not pyknotic. More importantly, all beclin-1/
Mcl1 positive cells were not TUNEL negative. These
results suggested that the colocalization of beclin-1
and Mcl1 may favor cell survival following focal cere-
bral ischemia.
Beclin-1 is essential for the initial steps of autophagy.
As one component of the class III phosphatidylinositol
kinase (PI3K), beclin-1 initiates autophagy through the
interaction with the other components of the PI3K path-
way. 3-MA is a relatively selective inhibitor of the
class III PI3K and has been shown to inhibit beclin-1-dependent autophagy in different disease models [19].
Pre-administration of 3-MA consistently inhibited the
conversion of LC3-I to LC3-II in the ischemic hemi-
sphere following MCAO. However, 3-MA did not affect
protein expression of Mcl1, suggesting that PI3K might
not be involved in the regulation of the interaction bet-
ween Mcl1 and beclin-1. One possible explanation is
that Mcl1 may interact with beclin-1 to protect against
cell death beyond the PI3K complex. Beclin-1 contains a
BH3 domain that is sufficient and essential for binding
to Bcl-2 homologs [20]. The interaction of Bcl-2 homo-
logs with the BH3 domain can prevent the release of
beclin-1, thereby inhibiting beclin-1-dependent autoph-
agy. By contrast, in the absence of Bcl-2 binding, beclin-
1 mutants induce excessive autophagy and promote cell
death [21]. Indeed, several Bcl-2 family proteins, such as
Bcl-2 and Bcl-XL, have been reported to inhibit beclin-
1-dependent autophagy through the interaction with the
BH3 domain of beclin-1. Given that beclin-1 is localized
primarily within cytoplasmic structures, including the en-
doplasmic reticulum, mitochondria and the perinuclear
membrane, and that Mcl1 is a mitochondrial protein [5],
it is highly possible that Mcl1 may interact with beclin-1
via the BH3 domain on mitochondria to prevent ischemic
cell death [8].
Conclusions
In summary, the present study demonstrates the ex-
pression and cellular localization of Mcl1 in the brains
of cerebral ischemia/reperfusion injury model rats. In
addition, our findings suggest that expression of Mcl1 is
associated with the survival of neurons following ische-
mic stroke. Mcl1 may inhibit cell death, at least partially
through colocalization with beclin-1.
Methods
Animals
All experimental procedures were approved by the
Institutional Animal Ethical Committee of Sun Yat-sen
University and were conducted according to the Guide
for the Care and Use of Laboratory Animal of the Na-
tional Institute of Health (Publication No. 80–23, revised
1996). A total of 60 male Sprague–Dawley rats weighing
250–300 g were purchased from the Center for Experi-
mental Animals of Sun Yat-Sen University. Rats were
randomly assigned into four groups: sham-operated con-
trol group (cont, n = 10), MCAO group (maco, n = 30),
MCAO +3-methyladenine (3-MA) group (3-MA, n = 10),
and MCAO + normal saline (NS) group (NS, n = 10).
MCAO Model
Rats were anesthetized with intraperitoneal (IP) injection
of 10% chloral hydrate (3 ml/kg body weight) and sub-
jected to MCAO as described previously, with minor
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made, and the right common carotid artery (CCA), ex-
ternal carotid artery (ECA) and internal carotid artery
(ICA) were isolated. The ECA was tied. A 4–0 mono-
filament nylon suture (Beijing Sunbio Biotech Co. Ltd,
Beijing, China) with a rounded tip was aseptically in-
serted from the right CCA to the ICA through the
stump of the ECA and gently advanced to occlude the
MCA. Recirculation/reperfusion of cerebral blood flow
was allowed by gently removing the monofilament after
1-hour ischemia, followed by different time intervals of
reperfusion. In sham-operated animals, all procedures
except occlusion of the MCA were performed. Core
body temperatures were monitored with a rectal probe
and maintained at 37°C during the whole procedure.
Following surgery, rats were allowed to recover sponta-
neous breathing and were kept in their cages with free
access to food and water. To evaluate impairment of
neuronal function after stroke, neurologic examinations
were performed 2,4, and 8 hours after the onset of oc-
clusion and then daily until sacrifice by a blinded exa-
miner who used a modified scoring system based on
that developed by Longa et al. [9]. The scoring system
used is as follows: 0, no deficits; 1, difficulty in fully
extending the contralateral forelimb; 2, unable to extend
the contralateral forelimb; 3, circling to the contrala-
teral side; 4, falling to the contralateral side; 5, did not
walk spontaneously and displayed a depressed level of
consciousness.3-Methyladenine administration
One hour before MCAO, rats in the 3-methyladenine
(3-MA) group were anaesthetized as above and mounted
on a stereotaxic apparatus. 3-Methyladenine (Sigma, St
Louis, MO, USA), an autophagy inhibitor, was dissolved
in 0.9% saline and injected into the left lateral ventricle
at a volume of 10 μL (600 nmol), as previously described
[2,10]. Animals in the vehicle group were anaesthetized
and injected with the same volume of normal saline.
Animals in the sham-operated and MCAO groups did
not receive any intraventricular injections.Tissue preparation
At 4, 24 and 72 hours after reperfusion, five rats from
each group were sacrificed under deep anesthesia with
10% chloral hydrate (5 ml/kg body weight, IP) and then
transcardially perfused with 0.9% sodium chloride at 4°C
followed by 4% paraformaldehyde in 0.01 M phosphate-
buffered saline (PBS, pH 7.4). Brains were then removed,
kept in the same fixative for 48 hours at 4°C and cryo-
protected in serial PBS isopropanol sucrose solutions
(20% and 30%) at 4°C until brains sank. Coronal sec-
tions (10 μm) were cut on a cryostat (CM1900; Leica,Heidelberger, Germany) and used for immunofluores-
cent staining.
Immunofluorescent labeling
For immunofluorescent assays, frozen sections (10 μm)
were prepared using a cryostat (Leica, CM1900) accor-
ding to standard procedures. The following antibodies
were used: rabbit anti-Mcl1 (1:1000; Abcam, Cambridge,
UK), mouse anti- Mcl1 (1:100; Santa Cruz Biotechnology,
Santa Cruz, CA), mouse anti-NeuN (1:400; Chemicon,
Temecula, CA), mouse anti-rat GFAP (1:800; Cell Sig-
naling Technology, Beverly, MA), mouse anti-rat OX-42
(1:300; Millipore, Billerica, MA, USA), mouse anti-rat
microtubule-associated protein1 light chain 3 (LC3; 1:100;
MBL, Japan), rabbit anti- LC3B (1:2000; Novus Biologi-
cals, USA), and mouse anti-caspase-3 (1:100; Santa Cruz
Biotechnology, Santa Cruz, CA). Immunofluorescence
was performed as described previously [11,12]. Briefly,
sections were pre-incubated with 0.3% Triton X-100
(v/v) in 0.01 M PBS (pH 7.4) for 10 minutes, followed
by blocking in 10% normal goat serum (KPL, USA)
or 1% bovine serum albumin (MPBIO) for 1 hour at
room temperature. Sections were then incubated over-
night at 4°C with primary antibodies diluted in primary
antibody diluents (Dako, Denmark). After rinsing in 0.01
M PBS (3 × 5 minutes), sections were incubated with
FITC-goat anti-rabbit IgG antibodies (1:250; KPL, USA)
or Alexa Fluor® 555 conjugated goat anti-rabbit IgG
(H + L), F(ab’)2 Fragment (1:1000; Cell Signaling Techno-
logy) or Alexa Fluor® 555 conjugated goat anti-mouse IgG
(H + L), F(ab’)2 Fragment (1:1000; Cell Signaling Tech-
nology) in 0.01M PBS for 1 hour at room temperature.
Finally, sections were thoroughly washed (3 × 5 minutes).
If necessary, sections were counterstained for nuclei with
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI;
1:1000; Roche, Mannheim, Germany), and then mounted
in ProLong® Gold antifade reagent (P36930, Invitrogen)
prior to imaging. Fluorescence signal was detected with a
microscope (BX51; Olympus). Negative control sections
were incubated with PBS instead of primary antibodies
and showed no positive staining.
Western blot experiments
The remaining rats in each group were sacrificed at 4,
24 and 72 hours after reperfusion (five rats in each
group). Rats were sacrificed under deep anesthesia with
10% chloral hydrate (5 ml/kg body weight, IP) and then
transcardially perfused with 0.9% sodium chloride at
4°C. Brains were then removed, the ipsilateral ischemic
cortex and striatum around the infarct area was rapidly
dissected from the brain tissue and then homogenized in
cell lysis buffer (Cell Signaling Technology, Danvers, MA,
USA) with complete protease inhibitor cocktail (Roche).
Protein (50 μg) extract from each sample was separated by
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ferred onto polyvinylidene fluoride membrane (Millipore).
Nonspecific binding was blocked with Tris-buffered saline
containing 0.1% Tween-20 (TBST) and 5% nonfat milk
(MERBCON, BCR685). The membranes were then incu-
bated with primary and secondary antibodies. Primary an-
tibodies used were as follows: rabbit anti-Mcl1 (1:2000;
Abcam), rabbit anti-beclin-1 (1:1000; Abcam), rabbit anti-
LC3B (1:2000; Novus Biologicals), and mouse monoclonal
anti-β-actin (1:3000; Proteintech Group Inc.). Secondary
antibodies used were horseradish peroxidase-conjugated
goat anti-mouse (1:6000; EarthOx, USA) or goat anti-
rabbit IgG antibodies (1:6000; EarthOx). Immunoreactivity
was detected with Chemiluminescent HRP Substrate
(Millipore) for 5 minutes and then exposed to Kodak
X-OMAT films. The exposed X-ray films were scanned.
Relative changes in protein expression were estimated
from mean pixel density using Image J 1.42q, normalized
to β-actin, and calculated as target protein expression/
β-actin expression ratios.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP
Nick-End Labeling (TUNEL)
Cell apoptosis was assessed using TUNEL staining. This
staining was performed using an in situ cell death detec-
tion kit (Roche Applied Science, Nonnenwald, Germany)
in accordance with the manufacturer’s instructions.
Briefly, brain sections were rinsed three times in PBS,
and then were incubated in 0.3% Triton X-100 (v/v) in
0.01 M PBS (pH 7.4) for 20 minutes at room tempe-
rature. Subsequently, the TUNEL reaction mixture was
then applied for 60 minutes at 37°C. Fluorescence signal
was detected using a fluorescence microscope (Olympus
BX51) at excitation/emission wavelengths of 492/520
nm (FITC, green).
Image analysis and quantification
All histological images were analyzed with Image-Pro
Plus image analysis software (Media Cybernetics, Silver
Spring, MD, USA) by one blinded assessor. The number
of immunostaining positive cells was counted using
Image-Pro Plus image analysis software in nine compar-
able, nonoverlapping fields (425 μm× 320 μm; 3 fields
per section × 3 sections per rat) under × 400 magnifica-
tion and was presented as the average cell number per
field on each section [11,12].
Statistical analysis
Data are presented as means ± standard deviation. Sta-
tistical analysis was performed by one-way analysis of
variance followed by Student’s t-test for post hoc ana-
lysis. Statistical analysis was performed with SPSS 13.0
for Windows (SPSS Inc., Chicago, IL, USA).Abbreviations
Mcl1: Myeloid cell leukemia 1; NS: Normal saline; MCAO: Middle cerebral
artery occlusion; CCA: Common carotid artery; ECA: External carotid artery;
ICA: Internal carotid artery; 3-MA: 3-methyladenine; DAPI: 4′, 6-diamidino-2-
phenylindole dihydrochloride; TUNEL: Terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling. LC3, microtubule-associated protein 1
light chain 3; IP: Ischemia-reperfusion.
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